Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SGN-40 (anti-huCD40 mAb), dacetuzumab
SGN-40 · 6 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| SGN-40 | DRUG | 1-8 mg/kg IV (in the vein) on Days 1, 4, 8, 15, 22 and 29 of Cycle 1; 8 mg/kg IV (in the vein) on Days 1, 8, 15, and 22 for Cycles 2-12. |
| rituximab | DRUG | 375 mg/m2 IV injection; Days -2, 8, 15 and 22 of Cycle 1 and Day 1 of Cycles 2-8. |
| gemcitabine | DRUG | 1000 mg/m2 IV Injection; Days 1 and 15 of all Cycles. |
| lenalidomide | DRUG | Up to 25 mg daily of a 21-day cycle. |
| dexamethasone | DRUG | 40 mg administered weekly. |
| SGN-40 (anti-huCD40 mAb) | DRUG | 1-8 mg/kg IV; Days 1, 4, 8, 15, 22, 29 of Cycle 1 and Days 1, 15, 29 and 43 of Cycles 2-6. |
Inclusion Criteria: * Diagnosis of DLBCL. * Received at least one combination chemotherapy regimen with rituximab, such as R-CHOP, R-ESHAP or equivalent. * Progression or relapse since most recent therapy. * At least one measurable lesion that is both greater than or equal to 2 cm by conventional C...
SGN-40 is an investigational monoclonal antibody developed by Pfizer, Inc. (ticker: PFE) for oncology indications. It has been studied in chronic lymphocytic leukemia, diffuse large B-cell lymphoma, multiple myeloma, and non-Hodgkin lymphoma. It is not approved and remains in clinical development.
SGN-40 has been studied in chronic lymphocytic leukemia, diffuse large B-cell lymphoma, multiple myeloma, and non-Hodgkin lymphoma. It is an investigational agent and is not approved for any indication. All clinical trials of SGN-40 have been completed.
SGN-40 is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer is the sponsor of the clinical trials evaluating SGN-40 in hematologic malignancies.
SGN-40 is in Phase 1 development. It is investigational and has not been approved by the FDA. Two Phase 1 trials and one Phase 2 trial have been completed, with no active trials ongoing.
SGN-40 has been evaluated in completed trials including NCT00655837 in diffuse large B-cell lymphoma, NCT00525447 in multiple myeloma, NCT00435916 in relapsed diffuse large B-cell lymphoma, and NCT00283101 in chronic lymphocytic leukemia. All trials are completed and no active trials are ongoing.
Yes, SGN-40 is also known as SGN-40 (anti-huCD40 mAb). Both names refer to the same investigational monoclonal antibody developed by Pfizer, Inc. for hematologic malignancies.